Naltrexone Dosing Regimens
For alcohol use disorder and opioid dependence, oral naltrexone is dosed at 50 mg once daily, while injectable naltrexone (Vivitrol) is administered as 380 mg intramuscularly once monthly; low-dose naltrexone (4.5 mg daily) is used off-label for chronic pain conditions.
Standard Dosing for Alcohol Use Disorder
Oral naltrexone 50 mg once daily is the FDA-approved dose for alcohol use disorder, typically continued for up to 12 weeks or longer based on clinical response 1, 2. This regimen has demonstrated efficacy in reducing relapse to heavy drinking with a number needed to treat of 18 to prevent one person from returning to any drinking, and 11 to prevent return to heavy drinking 3. The American Family Physician guidelines confirm this 50 mg daily dosing as standard practice 4.
Alternative Oral Dosing Schedules
For supervised administration settings where daily dosing is impractical, flexible regimens may be employed 1, 2:
- 50 mg every weekday with 100 mg on Saturday
- 100 mg every other day
- 150 mg every third day
However, extended dosing intervals carry a higher risk of hepatocellular injury with single doses above 50 mg, and the degree of opioid blockade may be reduced 1, 2.
Injectable Naltrexone Dosing
Injectable naltrexone (Vivitrol) is administered as 380 mg intramuscularly once monthly 4. This formulation is FDA-approved for both alcohol dependence and opioid dependence, with the advantage of improved medication adherence compared to daily oral dosing 5. Injectable naltrexone has demonstrated efficacy in reducing drinking days by approximately 5 days over a 30-day treatment period 3.
Opioid Dependence Dosing
Initiation Protocol
Treatment must begin with 25 mg of oral naltrexone as a test dose 1, 2. If no withdrawal signs occur, advance to 50 mg daily thereafter 1, 2. This cautious initiation is critical because naltrexone can precipitate severe withdrawal in opioid-dependent patients.
Opioid-Free Period Requirements
Patients must be opioid-free for a minimum of 7-10 days for short-acting opioids before starting naltrexone 1, 2. For patients transitioning from buprenorphine or methadone, they may be vulnerable to precipitated withdrawal for as long as 2 weeks 1, 2. The FDA labels explicitly warn that postmarketing case reports have documented severe manifestations of precipitated withdrawal when switching from opioid agonist therapy to naltrexone 1, 2.
Naloxone Challenge Test
Before initiating naltrexone in patients with questionable opioid-free status, a naloxone challenge test should be performed 1, 2:
Intravenous route:
- Inject 0.2 mg naloxone, observe for 30 seconds
- If no withdrawal, inject 0.6 mg naloxone, observe for 20 minutes
Subcutaneous route:
- Administer 0.8 mg naloxone, observe for 20 minutes
If any withdrawal signs appear (nausea, vomiting, sweating, pupillary dilation, anxiety, muscle aches), the test is positive and naltrexone must not be initiated 1, 2. Repeat the challenge in 24 hours.
Low-Dose Naltrexone (Off-Label)
Low-dose naltrexone at 4.5 mg daily is used off-label for chronic pain conditions including fibromyalgia, neuropathy, complex regional pain syndrome, and multiple sclerosis 6, 7. This dosing range (1-5 mg daily) exerts different pharmacodynamics than standard doses, reducing glial inflammatory response by modulating Toll-like receptor 4 signaling 7.
In a Veterans Affairs evaluation, low-dose naltrexone resulted in an average pain score reduction of 0.83 points over an average treatment duration of 123 days 6. Common adverse effects at this dose include vivid dreams, drowsiness, dizziness, and nausea, reported in 32% of patients 6.
Combination Therapy Considerations
Naltrexone combined with bupropion (naltrexone-bupropion ER) for obesity uses a different dosing regimen 4. Each tablet contains 8 mg naltrexone and 90 mg bupropion, with weekly titration from 1 tablet daily to a maintenance dose of 2 tablets twice daily (total daily dose: 32 mg naltrexone/360 mg bupropion) 4.
Hepatotoxicity Monitoring
Baseline liver function tests and monitoring every 3-6 months are recommended, as naltrexone has been associated with hepatocellular injury at supratherapeutic doses 4. The risk is particularly elevated with single doses exceeding 50 mg 1, 2.
Critical Contraindications
Naltrexone cannot be used in patients requiring opioid analgesia, as it will block pain relief and potentially precipitate withdrawal 4. For procedures requiring opioid analgesia (such as endoscopy with fentanyl), naltrexone-containing medications should be held beforehand 4.
Treatment Duration and Adjunctive Therapy
Naltrexone should be combined with psychosocial interventions and counseling for optimal outcomes 4. The Hepatology guidelines recommend naltrexone or acamprosate in combination with counseling to decrease relapse likelihood in patients with alcohol use disorder who achieve abstinence 4. While the optimal treatment duration is not definitively established, many clinicians recommend one year of treatment 8.